14 februari 2022:  2021; 2021: 1075513. Published online 2021 Oct 25.

Uit een gerandomiseerde fase II studie bij totaal 220 patiënten (in elke groep 110 patiënten) met gevorderde eierstokkanker (stadium III en IV) blijkt dat het effect van psychologische interventie in combinatie met voedingsrichtlijnen op kwaliteit van leven en overleving van een TCM aanpak het zogeheten Bushen Quyu-afkooksel (thee) bij de behandeling van deze patiënten hele goede resultaten laat zien. Op een 2-jaars meting was het verschil in overleving maar liefst 23 procent beter voor de studiegroep in vergelijking met de controlegroep. Overall verdubbelde het effect van de totale aanpak van 31 naar 64 procent. Met maar liefst 14 volledige remissies en 57 gedeeltelijke remissies.

Met als conclusie: Samenvattend kan het Bushen Quyu-afkooksel in combinatie met psychologische interventie en dieetbegeleiding voor de behandeling van patiënten met gevorderde eierstokkanker de negatieve emoties van de patiënt effectief verlichten, de immuunfunctie van de patiënt verbeteren, het niveau van tumormarkers verlagen en de kwaliteit van leven van de patiënt verder verbeteren en verpleegkundige tevredenheid, verbetering van het behandelingseffect en bevordering van de revalidatie van patiënten; het is een klinische toepassing waard.

Vertaald uit het studierapport zijn dit de resultaten:

  • Het totale effectieve behandelingspercentage in de observatiegroep (64,55%) was hoger dan die in de controlegroep (31,82%).
  • De verpleegkundige tevredenheid van de observatiegroep was 94,55%, de verpleegkundige tevredenheid van de controlegroep was 84,55% en het verschil was statistisch significant (p <0,01).
  • De therapietrouw van de observatiegroep was 98,18%, de therapietrouw van de controlegroep was 82,73% en het verschil was statistisch significant (p < 0,0001).
  • Na de verpleging waren de angst-zelfbeoordelingsschaal (SAS)-score en de zelfbeoordelingsdepressieschaal (SDS)-score van de twee groepen patiënten verlaagd (∗p <0,05), en de score van de observatiegroep significanter verlaagd (Δp < 0,05).
  • Na verpleging namen de scores van de twee groepen patiënten in sociale/familiale status, fysiek functioneren, fysiologisch functioneren en emotionele status toe (∗p <0,05), en de observatiegroep was significant hoger dan de controlegroep (Δp <0,05) .
  • Na verpleging waren de CD3+, CD4+, CD4+/CD8+ niveaus van de observatiegroep significant hoger dan de controlegroep (p < 0,05). Het CD8+-niveau van de observatiegroep was significant lager dan de controlegroep (p < 0,05).
  • Na borstvoeding waren de niveaus van tumormarkers in de twee groepen verlaagd (∗p <0,05), en de observatiegroep was significant meer gedownreguleerd dan de controlegroep (Δp <0,05).
  • Het cumulatieve overlevingspercentage van twee jaar van de observatiegroep was 78,18% en het cumulatieve overlevingspercentage van twee jaar van de controlegroep was 54,55%. De observatiegroep was significant hoger dan de controlegroep (p <0,05).
Het volledige studierapport dat gedetailleerd beschrijft hoe de studie werd uitgevoerd enz. is gratis in te zien. Klik daarvoor op de titel van het abstract:

Abstract

Objective

To study the effects of psychological intervention combined with dietary guidance on the quality of life and long-term efficacy of Bushen Quyu Decoction in the treatment of patients with advanced ovarian cancer.

Methods

220 patients with advanced (stages III to IV) ovarian cancer in our hospital from May 2015 to October 2018 were selected and randomly divided into a control group and an observation group, with 110 cases in each group. The patients in the control group received basic nursing care and treatment with Bushen Quyu Decoction, and the patients in the observation group were combined with psychological intervention and dietary guidance on the basis of the treatment of the patients in the control group. The clinical efficacy, nursing satisfaction, treatment compliance, quality of life, negative emotion comparison, and long-term efficacy of the two groups were compared. Moreover, the changes of immune function indexes and the content of tumor markers were compared between the two groups.

Results

The total effective rate of treatment in the observation group (64.55%) was higher than that in the control group (31.82%). The nursing satisfaction of the observation group was 94.55%, the nursing satisfaction of the control group was 84.55%, and the difference was statistically significant (p < 0.01). The treatment compliance of the observation group was 98.18%, the treatment compliance of the control group was 82.73%, and the difference was statistically significant (p < 0.0001). After nursing, the Anxiety Self-Rating Scale (SAS) score and Self-Rating Depression Scale (SDS) score of the two groups of patients were decreased (∗p < 0.05), and the score of the observation group decreased more significantly (Δp < 0.05). After nursing, the scores of the two groups of patients in social/family status, physical function, physiological function, and emotional status increased (∗p < 0.05), and the observation group was significantly higher than the control group (Δp < 0.05). After nursing, the CD3+, CD4+, CD4+/CD8+ levels of the observation group were significantly higher than the control group (p < 0.05). The CD8+ level of the observation group was significantly lower than the control group (p < 0.05). After nursing, the levels of tumor markers in the two groups were decreased (∗p < 0.05), and the observation group was downregulated more significantly than the control group (Δp < 0.05). The two-year cumulative survival rate of the observation group was 78.18%, and the two-year cumulative survival rate of the control group was 54.55%. The observation group was significantly higher than the control group (p < 0.05).

Conclusions

Psychological intervention combined with dietary guidance can significantly improve the quality of life and mental state of patients with advanced ovarian cancer, enhance the patient's immune function, reduce the serum tumor markers carcinoembryonic antigen (CEA) and carbohydrate antigen (CA199) levels, and improve survival rate and survival time, which has important clinical significance.

Acknowledgments

The authors deeply appreciate the contributions to this work made in various ways by all of the participants.

Data Availability

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Disclosure

The funding body had no role in the design of the study, collection, analysis, interpretation of data, or writing of the manuscript.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

1. Aleksandra Kujawa K., Lisowska K. M. [Ovarian cancer--from biology to clinic] Postępy Higieny Medycyny Doświadczalnej . 2015;69:1275–1290. doi: 10.5604/17322693.1184451. [PubMed] [CrossRef[]
2. Kossaï M., Leary A., Scoazec J. Y., Genestie C. Ovarian cancer: a heterogeneous disease. Pathobiology . 2018;85(1-2):41–49. doi: 10.1159/000479006. [PubMed] [CrossRef[]
3. Kroeger P. T., Jr., Drapkin R. Pathogenesis and heterogeneity of ovarian cancer. Current Opinion in Obstetrics & Gynecology . 2017;29(1):26–34. doi: 10.1097/gco.0000000000000340. [PMC free article] [PubMed] [CrossRef[]
4. Schulman-Green D., Ercolano E., Dowd M., Schwartz P., McCorkle R. Quality of life among women after surgery for ovarian cancer. Palliative and Supportive Care . 2008;6(3):239–247. doi: 10.1017/s1478951508000497. [PMC free article] [PubMed] [CrossRef[]
5. Sehouli J., Grabowski J. P. Surgery in recurrent ovarian cancer. Cancer . 2019;125(Suppl 24):4598–4601. doi: 10.1002/cncr.32511. [PubMed] [CrossRef[]
6. Wang R., Sun Q., Wang F., et al. Efficacy and Safety of Chinese herbal medicine on ovarian cancer after reduction surgery and adjuvant chemotherapy: a systematic review and meta-analysis. Frontiers in Oncology . 2019;9:p. 730. doi: 10.3389/fonc.2019.00730. [PMC free article] [PubMed] [CrossRef[]
7. Sun J., Liu J., Liu D., Wu X. Network pharmacology-based and clinically relevant prediction of the potential targets of Chinese herbs in ovarian cancer patients. BioMed Research International . 2020;2020:18. doi: 10.1155/2020/8965459.8965459 [PMC free article] [PubMed] [CrossRef[]
8. Gu Z., Qiu T., Yang S., Tian F., Wu H. A study on the psychological factors affecting the quality of life among ovarian cancer patients in China. Cancer Management and Research . 2020;12:905–912. doi: 10.2147/cmar.s239975. [PMC free article] [PubMed] [CrossRef[]
9. Kiechle M., Engel C., Berling A., et al. Effects of lifestyle intervention in BRCA1/2 mutation carriers on nutrition, BMI, and physical fitness (LIBRE study): study protocol for a randomized controlled trial. Trials . 2016;17(1):p. 368. doi: 10.1186/s13063-016-1504-0. [PMC free article] [PubMed] [CrossRef[]
10. Doubeni C. A., Doubeni A. R., Myers A. E. Diagnosis and management of ovarian cancer. American Family Physician . 2016;93:937–944. [PubMed[]
11. Marabelle A., Le D. T., Ascierto P. A., et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. Journal of Clinical Oncology . 2020;38(1):1–10. doi: 10.1200/jco.19.02105. [PMC free article] [PubMed] [CrossRef[]
12. O’Sullivan C. K., Bowles K. H., Jeon S., Ercolano E., McCorkle R. Psychological distress during ovarian cancer treatment: improving quality by examining patient problems and advanced practice nursing interventions. Nursing Research and Practice . 2011;2011:14. doi: 10.1155/2011/351642.351642 [PMC free article] [PubMed] [CrossRef[]
13. Clevenger L., Schrepf A., Degeest K., et al. Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis. Cancer . 2013;119(17):3234–3241. doi: 10.1002/cncr.28188. [PMC free article] [PubMed] [CrossRef[]
14. Fortner R. T., Schock H., Le Cornet C., et al. Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: results from the EPIC cohort. International Journal of Cancer . 2018;142(7):1355–1360. doi: 10.1002/ijc.31164. [PMC free article] [PubMed] [CrossRef[]
15. Elias K. M., Guo J., Bast R. C., Jr Early detection of ovarian cancer. Hematology/Oncology Clinics of North America . 2018;32(6):903–914. doi: 10.1016/j.hoc.2018.07.003. [PMC free article] [PubMed] [CrossRef[]
16. Eisenhauer E. A. Real-world evidence in the treatment of ovarian cancer. Annals of Oncology: Official Journal of the European Society for Medical Oncology . 2017;28:viii61–viii65. doi: 10.1093/annonc/mdx443. [PubMed] [CrossRef[]
17. Yang C., Xia B. R., Zhang Z. C., Zhang Y. J., Lou G., Jin W. L. Immunotherapy for ovarian cancer: adjuvant, combination, and neoadjuvant. Frontiers in Immunology . 2020;11 doi: 10.3389/fimmu.2020.577869.577869 [PMC free article] [PubMed] [CrossRef[]
18. Liu H., Shen M., Zhao D., et al. The effect of triptolide-loaded exosomes on the proliferation and apoptosis of human ovarian cancer SKOV3 cells. BioMed Research International . 2019;2019:14. doi: 10.1155/2019/2595801.2595801 [PMC free article] [PubMed] [CrossRef[]
19. Kwiatkowski F., Dessenne P., Laquet C., Daures J. P., Gay-Bellile M., Bignon Y. J. BRACAVENIR—impact of a psychoeducational intervention on expectations and coping in young women (aged 18–30 years) exposed to a high familial breast/ovarian cancer risk: study protocol for a randomized controlled trial. Trials . 2016;17(1):p. 509. doi: 10.1186/s13063-016-1642-4. [PMC free article] [PubMed] [CrossRef[]
20. Arden-Close E., Mitchell F., Davies G., et al. Mindfulness-based interventions in recurrent ovarian cancer: a mixed-methods feasibility study. Integrative Cancer Therapies . 2020;19 doi: 10.1177/1534735420908341.1534735420908341 [PMC free article] [PubMed] [CrossRef[]
21. Kim S., Aceti M., Baroutsou V., et al. Using a tailored digital health intervention for family communication and cascade genetic testing in Swiss and Korean families with hereditary breast and ovarian cancer: protocol for the DIALOGUE study. JMIR Research Protocols . 2021;10(6) doi: 10.2196/26264.e26264 [PMC free article] [PubMed] [CrossRef[]
22. Guo J., Yu J., Song X., Mi H. Serum CA125, CA199 and CEA combined detection for epithelial ovarian cancer diagnosis: a meta-analysis. Open Medicine . 2017;12(1):131–137. doi: 10.1515/med-2017-0020. [PMC free article] [PubMed] [CrossRef[]
23. Lertkhachonsuk A. A., Buranawongtrakoon S., Lekskul N., Rermluk N., Wee‐Stekly W. W., Charakorn C. Serum CA19 ‐9, CA ‐125 and CEA as tumor markers for mucinous ovarian tumors. Journal of Obstetrics and Gynaecology Research . 2020;46(11):2287–2291. doi: 10.1111/jog.14427. [PMC free article] [PubMed] [CrossRef[]
24. Hao C., Sui Y., Li J., Shi Y., Zou Z. The clinical value of the combined detection of enhanced CT, MRI, CEA, and CA199 in the diagnosis of rectal cancer. Journal of Oncology . 2021;2021:8. doi: 10.1155/2021/8585371.8585371 [PMC free article] [PubMed] [CrossRef[]
25. Zhao D. X., Chen P., Su C. H., et al. Efficacy of weekly paclitaxel for the treatment of advanced ovarian cancer: a protocol for systematic review and meta-analysis. Medicine . 2020;99(25) doi: 10.1097/md.0000000000020537.e20537 [PMC free article] [PubMed] [CrossRef[]
26. Li Y., Li J., Fan B., et al. Efficacy and safety of Yiqi Huoxue Jiedu decoction for the treatment of advanced epithelial ovarian cancer patients: a double-blind randomized controlled clinical trial. Journal of Traditional Chinese Medicine . 2020;40:103–111. [PubMed[]
27. Ge S., Xing Q., Zhang A., Wang Y. Effect of traditional Chinese medicine (TCM) on survival, quality of life, and immune function in patients with ovarian carcinoma. Medicine . 2021;100(2) doi: 10.1097/md.0000000000023904.e23904 [PMC free article] [PubMed] [CrossRef[]
28. Chan K. K. L., Yao T. J., Jones B., et al. The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring. Annals of Oncology . 2011;22(10):2241–2249. doi: 10.1093/annonc/mdq749. [PubMed] [CrossRef[]
29. Wu Y. H., Chen H. Y., Lai C. H., et al. Use of Chinese herbal medicine improves chemotherapy-induced thrombocytopenia among gynecological cancer patients: an observational study. Evidence-based Complementary and Alternative Medicine: eCAM . 2018;2018:8. doi: 10.1155/2018/4201325.4201325 [PMC free article] [PubMed] [CrossRef[]
30. Tao F., Ruan S., Liu W., Wang L., Xiong Y., Shen M. Fuling granule, a traditional Chinese medicine compound, suppresses cell proliferation and TGFbeta-induced EMT in ovarian cancer. PLoS One . 2016;11(12) doi: 10.1371/journal.pone.0168892.e0168892 [PMC free article] [PubMed] [CrossRef[]
31. Ojasoo T., Lippman M. E., Rochefort H., Namer M. Breast cancer: when tumor markers become targets for drugs. Annals of Oncology . 1993;4(3):195–198. doi: 10.1093/oxfordjournals.annonc.a058455. [PubMed] [CrossRef[]

Articles from Evidence-based Complementary and Alternative Medicine : eCAM are provided here courtesy of Hindawi Limited
 

Plaats een reactie ...

Reageer op "Psychologische interventie in combinatie met voedingsrichtlijnen plus Bushen Quyu-afkooksel verbetert 2-jaars overleving met 23 procent bij patiënten met gevorderde eierstokkanker"


Gerelateerde artikelen
 

Gerelateerde artikelen

Studiepublicaties van niet-toxische >> Psychologische interventie >> Kytogeen dieet bij patienten >> Dr. Felperlaan geeft adviezen >> Magnesium naast chemokuren >> Een vegetarisch vezelrijk >> Twee patienten met eierstokkanker >> Flavonoiden lijken beschermend >> Genisteine aglycone kan eierstokkanker >> Groene thee vergroot kansen >>